ChiCTR2500115548 版本V1.0 版本创建时间2025/12/29 08:45:21 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500115548 

最近更新日期:

Date of Last Refreshed on:

2025-12-29 08:45:02 

注册时间:

Date of Registration:

2025-12-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

脑卒中后不同高压氧疗干预策略下的上肢功能结局及作用机制研究:一项开放性优效性随机对照研究

Public title:

Study on Upper Limb Functional Outcomes and Mechanisms Under Different Hyperbaric Oxygen Therapy Strategies After Stroke: An Open-Label Superiority Randomized Controlled Trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

脑卒中后不同高压氧疗干预策略下的上肢功能结局及作用机制研究:一项开放性优效性随机对照研究

Scientific title:

Study on Upper Limb Functional Outcomes and Mechanisms Under Different Hyperbaric Oxygen Therapy Strategies After Stroke: An Open-Label Superiority Randomized Controlled Trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

林强 

研究负责人:

林强 

Applicant:

Qiang Lin 

Study leader:

Qiang Lin 

申请注册联系人电话:

Applicant telephone:

+86 189 2249 7674

研究负责人电话:

Study leader's
telephone:

+86 189 2249 7674

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

linqiang@sysush.com

研究负责人电子邮件:

Study leader's E-mail:

linqiang@sysush.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

深圳市光明区新湖街道圳园路628号

研究负责人通讯地址:

深圳市光明区新湖街道圳园路628号

Applicant address:

No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China

Study leader's address:

No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China

申请注册联系人邮政编码:

Applicant postcode:

518107

研究负责人邮政编码:

Study leader's postcode:

518107

申请人所在单位:

中山大学附属第七医院(深圳)

Applicant's institution:

The Seventh Affiliated Hospital of Sun Yat-sen University(Shenzhen)

研究负责人所在单位:

中山大学附属第七医院(深圳)

Affiliation of the Leader:

The Seventh Affiliated Hospital of Sun Yat-sen University(Shenzhen)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY-2025-357-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中山大学附属第七医院(深圳)医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the Seventh Affiliated Hospital of Sun Yat-sen University (Shenzhen)

伦理委员会批准日期:

Date of approved by ethic committee:

2025-06-25 00:00:00

伦理委员会联系人:

魏嘉亿

Contact Name of the ethic committee:

Jiayi Wei

伦理委员会联系地址:

广东省深圳市光明区新湖街道圳美社区海鑫光高新工业园F栋1楼

Contact Address of the ethic committee:

1st Floor, Building F, Haixinguang High-tech Industrial Park, Zhenmei Community, Xinhu Street, Guangming District, Shenzhen, Guangdong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 755 8120 7260

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中山大学附属第七医院(深圳)

Primary sponsor:

The Seventh Affiliated Hospital of Sun Yat-sen University(Shenzhen)

研究实施负责(组长)单位地址:

深圳市光明区新湖街道圳园路628号

Primary sponsor's address:

No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China, 518107

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

深圳

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

中山大学附属第七医院(深圳)

具体地址:

深圳市光明区新湖街道圳园路628号

Institution
hospital:

The Seventh Affiliated Hospital of Sun Yat-sen University(Shenzhen)

Address:

No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China, 518107

经费或物资来源:

中山大学附属第七医院 735 项目

Source(s) of funding:

The 735 Project of the Seventh Affiliated Hospital of Sun Yat-sen University

研究疾病:

脑卒中  

Target disease:

stroke

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.验证高压氧疗联合常规康复治疗改善脑卒中后上肢运动功能的有效性,并进一步明确不同高压氧疗方案的优效性 2.验证高压氧疗联合常规康复治疗可有效改善脑卒中后患者的功能结局 3.探究不同高压氧疗方案对于不同疾病阶段的脑卒中后患者功能结局影响的脑重塑机制  

Objectives of Study:

1. To verify the effectiveness of hyperbaric oxygen therapy combined with conventional rehabilitation in improving upper limb motor function after stroke, and to further determine the superiority of different hyperbaric oxygen therapy protocols. 2. To confirm that hyperbaric oxygen therapy combined with conventional rehabilitation can effectively improve the functional outcomes of stroke patients. 3. To explore the brain remodeling mechanisms by which different hyperbaric oxygen therapy protocols affect the functional outcomes of stroke patients at various stages of the disease.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 符合全国第四次脑血管病学术会议制订的脑卒中(包括脑出血和脑梗死)诊断标准; 2. 首次发病,并经头颅CT或MRI检查确诊为脑出血或脑梗死,2周≤病程≤6个月; 3. 年龄在18~80岁之间,包括18岁和80岁,性别不限; 4. 蒙特利尔认知评估量表(Montreal Cognitive Assessment, MoCA)≥18分,能配合完成实验; 5. 生命体征平稳;

Inclusion criteria

1. Meet the diagnostic criteria for stroke (including cerebral hemorrhage and cerebral infarction) established by the Fourth National Cerebrovascular Disease Academic Conference; 2. First-time occurrence, and confirmed by head CT or MRI to be cerebral hemorrhage or cerebral infarction, with a disease course of 2 weeks to 6 months; 3. Age between 18 and 80 years old, including both 18 and 80 years old, with no gender restrictions; 4. A score of 18 or higher on the Montreal Cognitive Assessment (MoCA), capable of cooperating and completing the experiment; 5. Stable vital signs.

排除标准:

1. 存在高压氧治疗禁忌证:未处理的气胸、肺大疱、开放性胸部外伤、服用双硫仑类药物或抗肿瘤药物、严重呼吸道感染、严重出血倾向、未控制的癫痫或高热。 2. 有恶性肿瘤、严重心、肝、肺、肾功能不全及内分泌、造血、免疫系统等严重原发性疾病; 3.严重精神疾患等原因导致无法理解指令,且无法配合。

Exclusion criteria:

1. There are contraindications to hyperbaric oxygen therapy: untreated pneumothorax, pulmonary bullae, open chest trauma, taking disulfiram or anticancer drugs, severe respiratory tract infections, severe bleeding tendencies, uncontrolled epilepsy, or high fever. 2. There are serious primary diseases such as malignant tumors, severe heart, liver, lung, kidney dysfunction, and endocrine, hematopoietic, and immune system disorders; 3. Severe mental illnesses that prevent understanding instructions and cooperation.

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2030-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-01 00:00:00 To 2030-12-31 00:00:00

干预措施:

Interventions:

组别:

低压治疗组

样本量:

70

Group:

Low-Pressure Treatment Group

Sample size:

干预措施:

进行常规上肢康复训练+医用空气加压氧舱(治疗压力设定为1.6ATA,加压10 min,稳压吸氧60 min,中间间歇2次吸舱内空气,每次5min,减压出舱10min。1次/天,10天/疗程,共3个疗程)

干预措施代码:

Intervention:

Conduct routine upper limb rehabilitation training + medical air pressure oxygen chamber (treatment pressure set at 1.6ATA, compression for 10 minutes, stable pressure oxygen inhalation for 60 minutes, with two intermittent breaks to breathe the chamber air, each lasting 5 minutes, and decompression out of the chamber for 10 minutes. 1 session/day, for 10 days per course of treatment, totaling 3 courses).

Intervention code:

组别:

高压治疗组

样本量:

70

Group:

High-Pressure Treatment Group

Sample size:

干预措施:

进行常规上肢康复训练+医用空气加压氧舱(治疗压力设定为2.2 ATA,加压15 min,稳压吸氧60 min,中间间歇吸舱内空气5min,减压出舱15min。1次/天,10天/疗程,共3个疗程)

干预措施代码:

Intervention:

Undertake routine upper limb rehabilitation exercises + medical air pressure hyperbaric oxygen chamber (treatment pressure set at 2.2 ATA, pressurization for 15 minutes, stable pressure oxygen inhalation for 60 minutes, with a 5-minute break to breathe the chamber air in between, and depressurization out of the chamber for 15 minutes. 1 session per day, for 10 days per treatment course, totaling 3 courses of treatment).

Intervention code:

组别:

对照组

样本量:

70

Group:

Control Group

Sample size:

干预措施:

进行常规上肢康复训练+舱外吸氧治疗(采用面罩吸氧,氧浓度为99.5%以上的医用氧,60分钟/天,1次/天,10天/疗程,共3个疗程)

干预措施代码:

Intervention:

Perform routine upper limb rehabilitation training + out-of-chamber oxygen therapy (using a mask for oxygen inhalation, with a medical oxygen concentration of over 99.5%, for 60 minutes per day, once a day, for 10 days per treatment course, with a total of 3 treatment courses).

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

中山大学附属第七医院(深圳) 

单位级别:

三甲 

Institution
hospital:

The Seventh Affiliated Hospital of Sun Yat-sen Universit(Shenzhen)

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

Fugl-Meyer上肢运动功能评定量表

指标类型:

主要指标

Outcome:

Fugl-Meyer Assessment of Upper Extremity, FMA-UE

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

美国国立卫生院卒中量表

指标类型:

次要指标

Outcome:

NlH Stroke Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

改良Barthel指数评定量表

指标类型:

次要指标

Outcome:

Modified Barthel Index, MBI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑卒中专用生活质量量表

指标类型:

次要指标

Outcome:

Stroke-Specific Quality of Life Scale, SS-QOL

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑血管事件再发生率

指标类型:

次要指标

Outcome:

Recurrence rate of cerebrovascular events.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

功能性近红外光谱技术

指标类型:

次要指标

Outcome:

functional near - infrared spectroscopy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用SAS 9.4 软件进行分层区组随机化,将符合纳入标准的210名受试者根据疾病阶段即亚急性期和恢复期1:1进行分层,并将分层之后的受试者按照1:1:1区组随机分为3组,分别是低压治疗组、高压治疗组和对照组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomization was performed using SAS 9.4 software with stratified block randomization. A total of 210 eligible participants were stratified 1:1 based on the disease stage, that is, the subacute phase and the recovery phase. After stratification, the participants were randomly assigned in a 1:1:1 block ratio into three groups: the low-pressure treatment group, the high-pressure treatment group, and the control group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-12-29 08:45:02